Jean Addington, Ph.D.

Dr Addington is Professor of Psychiatry at the University of Calgary in Alberta, Canada. She is an Alberta Innovates - Health Solutions (AIHS) Health Scientist. Dr Addington also holds the Novartis Chair for Schizophrenia Research at the University of Calgary.

Dr Addington has worked as a researcher, clinician and educator focusing on psychosis and schizophrenia for over 20 years. Dr Addington was instrumental in founding the Early Psychosis Program in Calgary, Alberta and directed that program until 2002. She helped establish the Prevention through Risk Identification, Management and Prevention (PRIME) clinics in Calgary and in Toronto, both community-based services dedicated to the early identification and treatment of individuals aged 12 to 30 who are at risk of developing psychosis.

Dr Addington's work focuses on finding predictors and mechanisms of conversion to psychosis. Working with young adults and adolescents as young as 13, she has sought to determine whether symptoms can be predicted and treated prior to a full blown psychotic episode.

 

There are several ongoing projects within Dr Addington's At-Risk for Mental Illness Research Program. The NAPLS project is a longitudinal study of predictors and mechanisms of conversion to psychosis. This study investigates both potential clinical and biological markers of conversion to psychosis that includes clinical assessments, traumatic events, substance use, social functioning, cognitive functioning, evoked potentials, genomics, cortisol and brain imaging. REGROUP is a skills training and supportive therapy trial offering group treatment to youth and young adults at risk of psychosis. PROCAN is a longitudinal study of both clinical predictors and biomarkers of developing a mental illness in youth at risk. Several treatment options such as cognitive remediation, social skills group treatment and exercise are being tested for their effectiveness in this high risk group.